MyFinsight
Home
Blog
About
Maturities of marketable
securities
$37,653K
(-74.90%↓ Y/Y)
Proceeds from issuance of
common stock under...
$356K
(18.27%↑ Y/Y)
Proceeds received on
pending sale of...
$450K
Net cash (used in)
provided by investing...
$13,779K
(4.74%↑ Y/Y)
Net cash provided by
financing activities
$356K
(18.27%↑ Y/Y)
Canceled cashflow
$24,324K
Net decrease in
cash, cash...
-$1,904K
(87.81%↑ Y/Y)
Canceled cashflow
$14,135K
Impairment of long-lived
assets
$5,086K
Stock-based compensation
expense
$3,271K
(-45.86%↓ Y/Y)
Prepaid expenses and
other current assets
-$2,242K
(-45.21%↓ Y/Y)
Accounts payable
$975K
(66.10%↑ Y/Y)
Other assets
-$537K
(-26950.00%↓ Y/Y)
Depreciation expense
$216K
(-69.01%↓ Y/Y)
Purchases of marketable
securities
$24,216K
(-82.30%↓ Y/Y)
Purchases of property and
equipment
$108K
(66.15%↑ Y/Y)
Net cash used in
operating activities
-$16,039K
(44.84%↑ Y/Y)
Canceled cashflow
$12,327K
Net loss
-$26,179K
(25.10%↑ Y/Y)
Accrued expenses and
other liabilities
-$1,047K
(61.97%↑ Y/Y)
Net accretion of
discounts on marketable...
$811K
(-59.12%↓ Y/Y)
Operating lease assets and
liabilities
$329K
(-6.80%↓ Y/Y)
Back
Back
Cash Flow
Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. (FULC)
source: myfinsight.com